Immune checkpoint inhibitors, such as monoclonal antibodies, and fusion proteins can block the binding of immune checkpoints by targeting PD-1 or PD-L1 to reactive T cells to eliminate tumor cells. This evidence concerns the gene CD274 and neoplasm.